Altogether, our data suggest that co-targeting of BRD/BET proteins in concert with BRAF/MEK inhibitors is likely to promote more durable responses of targeted therapy for BRAF-mutant melanoma in vivo. This evidence concerns the gene BRAF and melanoma.